Terkko Navigator / -/ Feeds / " ankylosing "

Patient-reported adherence to physical exercises of patients with ankylosing spondylitis

Lessons learned from a pilot implementation of physical activity recommendations in axial spondyloarthritis exercise group therapy

Highlights from the literature

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Secukinumab, an Interleukin-17A Inhibitor, in ankylosing Spondylitis

Healthcare, Vol. 10, Pages 132: Effectiveness of Physiotherapy in Patients with ankylosing Spondylitis: A Systematic Review and Meta-Analysis

STAT3 and SPI1, may lead to the immune system dysregulation and heterotopic ossification in ankylosing spondylitis

Prediction of Vertebral Fractures by Trabecular Bone Score in Patients With ankylosing Spondylitis

Clinical experience with the European ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety

Survival of disease-modifying antirheumatic drugs used as the first antirheumatic medication in the treatment of ankylosing spondylitis in Finland. A nationwide population-based register study

Ankyloserande spondylit: behandling med biologiska mediciner; en registerstudie

Ankylosing Spondylitis and the Risk of Hip Fractures: a Matched Cohort Study

Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci.

Ankylosing spondylitis: current approaches to treatment.

Ankylosing spondylitis: current approaches to treatment.

Ankylosing Spondylitis and Spinal Cord Injury.

Epistatic interactions between killer immunoglobulin-like receptors and human leukocyte antigen ligands are associated with ankylosing spondylitis

Ankylosing spondylitis: current approaches to treatment

Might axial myofascial properties and biomechanical mechanisms be relevant to ankylosing spondylitis and axial spondyloarthritis?

Positive association of Parkinson’s disease with ankylosing spondylitis: a nationwide population-based study

Bioinformatics Analysis of the Molecular Mechanism and Potential Treatment Target of ankylosing Spondylitis

JCM, Vol. 10, Pages 3354: Intestinal Microbial Metabolites in ankylosing Spondylitis

Benefit of Biological Drugs for Quality of Life in Patients with ankylosing Spondylitis: A Systematic Review and Meta-Analysis of Clinical Trials.

Effectiveness of Global Postural Reeducation in ankylosing Spondylitis: A Systematic Review and Meta-Analysis.

Etanercept in the Longterm Treatment of Patients With ankylosing Spondylitis.

Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci.

Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility.

JCM, Vol. 9, Pages 2696: Effectiveness of Global Postural Reeducation in ankylosing Spondylitis: A Systematic Review and Meta-Analysis

Coincident remission of ankylosing spondylitis after autologous stem cell transplantation for multiple myeloma

Safety and Efficacy of Intravenous Golimumab in Adults with ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.

Quality of internet videos related to exercise therapy of ankylosing spondylitis from mainland China

Magnetic Resonance Imaging Assessment of Spinal Inflammation in Patients Treated for ankylosing Spondylitis.

Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis.

The European ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab.

Secukinumab, an Interleukin-17A Inhibitor, in ankylosing Spondylitis.

Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries.

Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence

Gait characteristics in patients with ankylosing spondylitis: a systematic review.

Potential regulatory factors in the pathogenesis of ankylosing spondylitis.

Validation of the ankylosing Spondylitis Quality of Life assessment tool in patients with non-radiographic axial spondyloarthritis.

Autoantibodies against Protein Phosphatase Magnesium-Dependent 1A as a Biomarker for Predicting Radiographic Progression in ankylosing Spondylitis Treated with Anti-Tumor Necrosis Factor Agents.

Prevalence of low bone mineral density in ankylosing spondylitis, correlation with disease activity, and serum sclerostin levels

Pregnancy outcomes in women with ankylosing spondylitis: a scoping literature and methodological review

Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries

Vagal Nerve Stimulation-Modulation of the Anti-Inflammatory Response and Clinical Outcome in Psoriatic Arthritis or ankylosing Spondylitis

Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis

JCM, Vol. 10, Pages 4568: Impact of Infliximab Biosimilar CT-P13 Dose and Infusion Interval on Real-World Drug Survival and Effectiveness in Patients with ankylosing Spondylitis

Management of spine fractures in ankylosing spondylitis and diffuse idiopathic skeletal hyperostosis: a challenge

Comparison of the antibacterial activity of Australian Terminalia spp. extracts against Klebsiella pneumoniae: a potential treatment for ankylosing spondylitis